Processa Pharmaceuticals, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
Processa Pharmaceuticals, Inc. (PCSA) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of -$37.75 thousand as of 2019-12-31, per its 10-K filed 2020-03-06.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2020-03-06
- 2019-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net -$37.75K.
- 2018-12-31: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net -$37.75K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2019-12-31 | -$37.75K 10-K · filed 2020-03-06 |
| 2018-12-31 | -$37.75K 10-K/A · filed 2019-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |